Emerging Technologies: CRISPR-Cas9 editing of GPNMB in glioblastoma cells reduced invasion by 70%, while nanoparticle-mediated delivery of GPNMB siRNA improved targeting and reduced off-tumor effects in lung cancer models (Tuo et al., 2024). This evidence concerns the gene GPNMB and glioblastoma.